Riskpilot← Back to searchSign inGet full accessHäggström Life Science AB
ABActiveOrg 5568736598Krokslättsgatan 23Engineering activities and related technical consultancy · NACE 7112Est. 20111 employees
Revenue 2025
SEK 422K
+14% vs 2024
EBITDA margin
72.2%
+43% vs 2024
Equity ratio
68.4%
Financial strength
Net profit 2025
SEK 183K
-31% vs 2024
| Revenue | SEK 422K | +14% |
| EBITDA | SEK 305K | +43% |
| Net profit | SEK 183K | -31% |
| Total assets | SEK 2M | +2% |
| Equity | SEK 1,3M | -2% |
| Employees | 1 | — |
Legal name
Häggström Life Science AB
Org number
5568736598
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
29 november 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget skall bedriva konsultverksamhet och rådgivning inom projektledning, teknik, kvalitetsledning, företagsledning samt erbjuda utbildning och utöva styrelsearbete.
Address
Krokslättsgatan 23
Email
margareta.haggstrom@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 741 | 338 | 168 | 370 | 422 |
| Staff expenses | — | — | — | −43 | −43 |
| EBITDA | 603 | 211 | 64 | 213 | 305 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 603 | 211 | 64 | 213 | 305 |
| Net financials | — | 6 | 34 | 27 | 3 |
| Profit before tax | 508 | 167 | 98 | 341 | 233 |
| Tax | −107 | −36 | −24 | −75 | −50 |
| Net profit | 401 | 131 | 74 | 266 | 183 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 180 | 2 083 | 1 895 | 1 912 | 1 951 |
| Equity | 1 470 | 1 421 | 1 305 | 1 361 | 1 335 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 240 | 142 | 70 | 131 | 121 |
| Total debt | 240 | 142 | 70 | 131 | 121 |
EBITDA margin
72.2%
This company
15.8%
Market median
+357% vs market
20212025
Equity ratio
68.4%
This company
38.2%
Market median
+79% vs market
20212025
Return on equity
13.7%
This company
18.4%
Market median
+26% vs market
20212025
Net profit margin
43.4%
This company
8.1%
Market median
+436% vs market
20212025
Asset turnover
0.22×
This company
1.12×
Market median
-80% vs market
20212025
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Häggström Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Albert Sörensson Häggström | Deputy Board Member | 0 companies |
| Sören Lennart Haraldsson | Board of Directors | 0 companies |
| Hildur Margareta Häggström | Chairman | 0 companies |